Evaluation of Remdesivir in Liver Functions Covid-19 Patients At Bhayangkara H.S Samsoeri Mertojoso Hospital Surabaya
Kata Kunci:
remdesivir, covid-19, hepatotoxicityAbstrak
Referensi
K. Renu, P. L. Prasanna, and A. V. Gopalakrishnan, “Coronaviruses pathogenesis, comorbidities and multi-organ damage – A review,” Life Sciences, no. January, p. 117839, 2020.
H. Chu et al., “Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study,” Lancet Microbe, no. January, pp. 19–21, 2020.
Z. Wang, W. Qiang, and H. Ke, “A Handbook of 2019-nCoV Pneumonia Control and Prevention,” Hubei Science and technology press, pp. 1–108, 2020.
C. Ceraolo and F. M. Giorgi, “Genomic Variance of the 2019-nCoV Coronavirus,” Journal of Medical Virology, vol. 92, no. 5. pp. 522–528, 2020. doi: 10.1002/jmv.25700.
M. Hoffmann, H. Kleine-Weber, N. Krüger, M. Müller, C. Drosten, and S. Pöhlmann, “The Novel Coronavirus 2019 (2019-nCoV) Uses the SARS-coronavirus Receptor ACE2 and the Cellular Protease TMPRSS2 for Entry into Target Cells,” bioRxiv, 2020, doi: 10.1101/2020.01.31.929042.
A. D. Nardo, M. S. May, E. D. Dixon, S. F. Lax, and M. Trauner, “Pathophysiological mechanisms of liver injury in COVID-19,” no. November, pp. 1–13, 2020, doi: 10.1111/liv.14730.
K. Yang, B. A. Howell, J. Y. Feng, D. Babusis, T. Cihlar, and S. Q. Siler, “Assessment of the Mechanism for Remdesivir-Associated Clinical ALT Elevations Using DILIsym Quantitative Systems Toxicology Modeling,” vol. 13, p. 2020, 2020.
E. Burhan et al., Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020. 2020. [Online]. Available: https://www.papdi.or.id/download/983-pedoman-tatalaksana-covid-19-edisi-3-desember-2020
T. Haitao et al., “COVID-19 and Sex Differences: Mechanisms and Biomarkers,” MAYO CLINIC PROCEEDINGS, vol. 95, no. 1, pp. 2189–2203, 2020, [Online]. Available: http://www.akrabjuara.com/index.php/akrabjuara/article/view/919
M. J. Nasiri et al., “COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis,” Frontiers in Medicine, vol. 7, no. July, pp. 1–10, 2020, doi: 10.3389/fmed.2020.00459.
PDPI, PERKI, PERDATIN, IDAI, and PAPDI, “Revisi Protokol Tatalaksana COVID?19,” 2021.
Yao Na et al., “Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region,” Chinese Journal of Hepatology, vol. 28(03), pp. 234–239, 2020, doi: doi: 10.3760/cma.j.cn501113-20200226-00070.
Y. J. Wong et al., “A systematic review and meta-analysis of the COVID-19 associated liver injury,” Annals of Hepatology, vol. 19, no. 6, pp. 627–634, 2020, doi: 10.1016/j.aohep.2020.08.064.
C. A. Philips et al., “Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care,” Journal of Clinical and Translational Hepatology, vol. 000, no. 000, pp. 000–000, 2021, doi: 10.14218/jcth.2020.00110.
J. G. Stoffolano, “Hematological and Biochemical Factors Predicting SARS Fatality in Taiwan,” Elsevier & Formosan Medical Association, pp. 439–450, 2006.
A. Delgado et al., “Characterisation of drug-induced liver injury in patients with covid-19 detected by a proactive pharmacovigilance program from laboratory signals,” Journal of Clinical Medicine, vol. 10, no. 19, 2021, doi: 10.3390/jcm10194432.
EMA, “Summary on Compassionate Use Remdesivir Gilead International Nonproprietary Name: Remdesivir,” European Medicines Agency, vol. 31, no. April, p. 41, 2020, [Online]. Available: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf
A. Rezagholizadeh, S. Khiali, P. Sarbakhsh, and T. Entezari-Maleki, “Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis,” European Journal of Pharmacology, no. January, p. 173926, 2021.
J. H. Beigel et al., “Remdesivir for the Treatment of Covid-19 — Final Report,” New England Journal of Medicine, vol. 383, no. 19, pp. 1813–1826, 2020, doi: 10.1056/nejmoa2007764.
J. Grein et al., “Compassionate Use of Remdesivir for Patients with Severe Covid-19,” New England Journal of Medicine, vol. 382, no. 24, pp. 2327–2336, 2020, doi: 10.1056/nejmoa2007016
Unduhan
Diterbitkan
Terbitan
Bagian
Cara Mengutip
Artikel paling banyak dibaca berdasarkan penulis yang sama
- Risa Septinia, Didik Hasmono, Covid-19 and Its Vaccine Development: A Narrative Review , Jurnal Sains dan Kesehatan: Vol 3 No 6 (2021): J. Sains Kes.